Future Outlook
For your patients, an unmet need remains for a new standard of care for patients with R/R PCNSL1-3

FDA-approved therapies indicated for R/R PCNSL are urgently needed

  • There is no accepted standard of care3,4
  • Many patients will experience relapsed or refractory disease and may be ineligible for further intensive treatment due to age, poor performance status, or comorbidities2
  • Outcomes among older patients have remained poor and largely unchanged for decades5,6
arrow

Treating R/R PCNSL Remains a Major Area of Unmet Clinical Need1,2

Advancement in the understanding of 
R/R PCNSL is paramount

  • Current therapeutic knowledge is based on a small number of prospective, multicenter studies1,2,7
  • Participation in clinical trials is the key recommendation from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1,2,7,8*
    • Delayed diagnosis of patients can impact inclusion
    • Older age, poor performance status, and comorbidities may disqualify patients
  • Understanding of PCNSL pathobiology is not well established2,7
  • However, recent discoveries have provided targets for drug development, and clinical studies are underway1,2,9
Illustration depicting the complex treatment pathways for primary central nervous system lymphoma (PCNSL)

Deciphera is rising to the challenge

View expert opinions, videos, and downloadable resources

Go to resources

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†May include targeted agents, immunomodulatory agents, or other monotherapy/combination regimens.2

‡Also a type of chemotherapy.

Not all drugs within the presented classes are used in the treatment of R/R PCNSL.

ASCT=autologous stem cell transplantation; BTKi=Bruton tyrosine kinase inhibitor; FDA=Food and Drug Administration; IMiDs=immunomodulatory drugs; mAbs=monoclonal antibodies; NCCN=National Comprehensive Cancer Network; PCNSL=primary central nervous system lymphoma; R/R PCNSL=relapsing or refractory primary central nervous system lymphoma; WBRT=whole brain radiation therapy.

References: 1. Tao K, Wang X, Tian X. Relapsed primary central nervous system lymphoma: current advances. Front Oncol. 2021;11:649789. doi:10.3389/fonc.2021.649789 2. Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20 3. Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303. doi:10.1093/neuonc/now033 4. Mendez JS, Grommes C. Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules. Am Soc Clin Oncol Educ Book. 2018;38:604-615. doi:10.1200/EDBK_200829 5. Liu Y, Yao Q, Zhang F. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (review). Int J Oncol. 2021;58(3):371-387. doi:10.3892/ijo.2021.5180 6. Kaulen LD, Baehring JM. Treatment options for recurrent primary CNS lymphoma. Curr Treat Options Oncol. 2022;23(11):1548-1565. doi:10.1007/s11864-022-01016-5 7. Ferreri AJM. How I treat primary CNS lymphoma. Blood. 2011;118(3):510-522. doi:10.1182/blood-2011-03-321349 8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.1.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 18, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org 9. Seidel S, Kowalski T, Nilius-Eliliwi V, Schroers R, Schlegel U. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis. Neurol Res Pract. 2023;5(1):8. doi:10.1186/s42466-023-00234-y